Full-Time

Director, New Product Planning

Posted on 11/15/2025

Lundbeck

Lundbeck

5,001-10,000 employees

Global neuroscience-focused pharmaceutical company

Compensation Overview

$200k - $240k/yr

+ Bonus Target 25% + Long-Term Incentive Plan

Highland Park, IL, USA

Hybrid

Category
Business & Strategy (1)
Required Skills
Market Research
Forecasting
Requirements
  • An accredited Bachelor's degree is required.
  • Eight or more years of pharmaceutical or biopharmaceutical field experience, with at least four years working in a Commercial organization.
  • Ability to coordinate and manage multiple projects simultaneously.
  • Proven success in developing clear, actionable steps aligned to overall business strategy.
  • Collaborative team player with ability to build trusted partnerships, manage stakeholders and meet shared objectives.
  • Strong analytical skills with a demonstrated ability to generate actionable and innovative strategic insights.
  • Ability to use informed, sound judgment and make timely, effective decisions under conditions of uncertainty.
  • Impactful oral and written communication skills with the ability to persuade and influence others.
  • Accepts clear responsibility and accountability for results.
Responsibilities
  • Partners with Global New Asset Strategy, U.S. Pipeline and Forecasting, Business Development, and U.S./Global Medical to assess internal pipeline and external asset opportunities for U.S. launch readiness.
  • Represents the US as a member of Commercial/Access/Medical (CAM team) within GPT, specifically late lifecycle pipeline assets.
  • Acquires comprehensive insights into market size and opportunities, competitive overview and landscape, payer environment, unmet needs, and ongoing competitive intelligence for the disease areas in scope.
  • Leads the identification of key customers, KOLs and patient advocacy organizations, and meets with them as needed to help assess opportunities.
  • Provides strategic input to guide primary and secondary market research in understanding full opportunity size and market potential.
  • Develops and executes comprehensive launch plans for late-stage assets in collaboration with appropriate stakeholders.
  • Works closely with Associate Director, US New Product Planning to increase internal capabilities and deliver evaluation excellence for business cases and commercial evaluations.
  • Collaborates closely with the US Market Access and Pricing team, as well as Government Affairs, to gather insights on potential impacts to future cases (e.g., IRA).
  • Establishes and effectively collaborates with global business development, global new asset strategy and across US functions including Commercial, Medical and others.
  • Partners closely with US Pricing team to ensure pricing, market access, and gross-to-net assumptions are taken into account for each case.
  • Collaborates with members of the Research and Development and Medical organization to ensure appropriate Target Product Profile development, specifically clinical trial endpoints.
  • Develops and nurtures strong working relationships with a broad range of medical, marketing, market access, forecasting, finance, and business development colleagues to ensure stakeholder buy-in and data-driven decision making.
  • Leads cross-functional matrix project teams by establishing priorities, setting objectives, and driving alignment to strategic goals.
  • Develops and oversees metrics and key success indicators; proactively identifies and removes obstacles.
Desired Qualifications
  • An accredited Bachelor's degree in Marketing or related field, or an accredited MBA.
  • Relevant pharmaceutical experience, particularly in market access, business development, or commercial roles.
  • International/Global experience.
  • Strong preference for candidate to be based in Deerfield, Illinois.

Lundbeck is a global pharmaceutical company that focuses on brain health. It develops and markets prescription medicines for central nervous system (CNS) disorders such as depression, schizophrenia, and other brain diseases, using its in-house research and development to advance its pipeline. Its products work by altering brain chemistry or signaling to reduce symptoms and improve function, delivered in standard medical formats like oral tablets or other approved forms. Lundbeck differentiates itself through a specialized focus on neuroscience, a long-standing commitment to R&D, and a strong, founder-aligned foundation that supports long-term scientific work rather than short-term gains. Its goal is to restore brain health and improve quality of life for people with neurological and psychiatric conditions by advancing neuroscience and delivering effective therapies globally.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Copenhagen, Denmark

Founded

1915

Simplify Jobs

Simplify's Take

What believers are saying

  • VYEPTI and Rexulti growth are driving strong 2026 commercial momentum.
  • Cradle partnership can accelerate antibody discovery for two CNS programs.
  • Lu AF28996 and amlenetug create nearer-term and rare-disease pipeline catalysts.

What critics are saying

  • VYEPTI concentration exposes Lundbeck to payer pressure and CGRP class competition.
  • Lu AF28996 remains early-stage; Phase 2 failure would damage pipeline credibility.
  • Amlenetug faces high attrition risk in MSA, a fast-progressing disease with no approved therapies.

What makes Lundbeck unique

  • Exclusive focus on brain health gives Lundbeck concentrated neuroscience expertise.
  • Lundbeck combines established brands with emerging CNS and Parkinson's pipeline assets.
  • The Lundbeck Foundation's control supports long-term R&D discipline.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Lundbeck who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Plesner
Jun 4th, 2026
Lundbeck refinances $791M credit facility with Nordic and international lenders

Plesner has advised Danish pharmaceutical company Lundbeck on refinancing its €700 million multicurrency revolving credit facility. The transaction replaces Lundbeck's existing facility and strengthens the company's financing platform to support ongoing operations and future strategic initiatives. The deal was completed with a syndicate of Nordic and international lenders, including Danske Bank, Bank of America, BNP Paribas, Nordea, SEB and Jyske Bank. The Plesner advisory team consisted of Henrik Kure, Anne Bro Kristensen and Nanna Cecilie Steenberg, working with Lundbeck's treasury team led by Peter Kreutzfeldt and Christian Kjærgaard.

CDO Magazine
Apr 2nd, 2026
This week's leadership moves: HSBC, Lundbeck, and Kimberly-Clark.

This week's leadership moves: HSBC, Lundbeck, and Kimberly-Clark. Updated 11:54 PM PDT, April 2, 2026 Each week, CDO Magazine curates a high-level overview of executive appointments and leadership transitions shaping the global data, AI, and analytics ecosystem. This roundup offers a quick-read snapshot of how leadership talent is transitioning across organizations as they evolve data and AI strategies to support digital transformation, data management, enterprise innovation, security, and AI-driven decision-making. This briefing tracks leadership movements involving Chief Data Officers, Chief Artificial Intelligence Officers, Chief Data and Analytics Officers, Chief Information Officers, Chief Information Security Officers, and senior executives responsible for data, analytics, security, and digital strategy across industries. For the week of March 30, highlighted in this edition, we feature key leadership updates at HSBC, Lundbeck, and Kimberly-Clark, alongside several other notable appointments recently spotlighted on CDO Magazine. This week's featured moves: Global pharmaceutical company Lundbeck has promoted Markus Kede to Senior Vice President and Chief AI Officer. In this new role, Kede joins the Executive Leadership Team to drive a global AI strategy aimed at transforming Lundbeck into a "bionic company." Formerly the SVP of Finance & Business Planning for Lundbeck US, Kede will oversee responsible AI governance and the integration of machine learning across drug discovery and commercial operations. Kimberly-Clark has welcomed Francesco Tinto as Chief Information and Global Business Services (GBS) Officer. Reporting to the President and COO, Tinto will lead the digital and operational initiatives supporting the company's "Powering Care" strategy. Tinto brings over 30 years of expertise, including previous global CIO roles at Walgreens Boots Alliance and Kraft Heinz, where he specialized in technology integration and business process optimization. Discovery Education has appointed Kara Schlageter as its first-ever Chief Information Security Officer. Schlageter, who brings over 25 years of experience in cybersecurity and enterprise risk, is tasked with embedding "secure-by-design" principles into the company's digital learning solutions. Her leadership will focus on maintaining trust and privacy for educators and students as the organization accelerates its AI-driven innovations. HSBC Holdings plc has named David Rice as its first Chief AI Officer, effective April 1. In this newly created role, Rice will lead enterprise-wide AI adoption to support the bank's ambition of building a future-ready institution. Formerly the COO for HSBC's Corporate and Institutional Banking business, Rice is tasked with scaling generative AI tools and streamlining processes while ensuring human accountability and responsible use. Manulife has appointed Dr. Hongjuan Liu as Chief AI & Data Officer for Hong Kong and Macau. Dr. Liu, who joins from McDonald's China, will lead a cross-functional team to establish Hong Kong as a regional AI Centre of Excellence. With over 20 years of experience, he will oversee advanced analytics and AI deployment initiatives to deliver greater value for customers and distribution partners across both markets. The Department of War has announced the appointment of Gavin Kliger as Chief Data Officer. A key figure in the Department's AI roadmap, Kliger previously contributed to the Department of Government Efficiency team and the launch of the GenAI.mil platform. In his new capacity, he will bridge private-sector innovation with military operational expertise to accelerate the delivery of advanced data and AI capabilities to the warfighter.

Clival Private Limited
Mar 18th, 2026
Lundbeck advances Parkinson's pipeline with promising early data.

Lundbeck advances Parkinson's pipeline with promising early data. Early-stage data. New mechanisms. And a continued push into complex brain disorders. H. Lundbeck A/S has announced encouraging Phase 1b results for its investigational Parkinson's drug Lu AF28996, with findings set to be presented at the AD/PD 2026 Conference in Copenhagen. What the Phase 1b trial Showed? The study focused on patients with advanced Parkinson's disease, a stage where treatment becomes increasingly complex. Key takeaways. * Well tolerated in patients * Showed early signs of biological activity * Supports continued clinical development This was a proof-of-mechanism trial, meaning the goal wasn't just safety - but also to confirm that the drug behaves as intended in the body. Why This drug matters? Parkinson's treatment still has major gaps. The core problem. Patients with advanced disease often experience: * Motor fluctuations * "OFF" time (periods of reduced mobility) * Drug-induced complications like dyskinesia Even existing therapies: * Lose effectiveness over time * Require complex delivery systems * Come with tolerability issues The approach: continuous dopamine stimulation. Lu AF28996 is designed differently. Mechanism. * Targets dopamine D1 and D2 receptors * Aims to deliver continuous dopaminergic stimulation * Oral administration (simpler than device-based therapies) Potential benefits. * Reduce "OFF" time * Improve motor control * Lower risk of treatment-induced complications In short: smoother symptom control with fewer trade-offs. What's next? Lundbeck is moving forward quickly. * Phase 2 trial planned for 2026 * Focus: patients with advanced Parkinson's disease Still early - but promising enough to justify the next step. Beyond Parkinson's: Focus on Multiple System Atrophy (MSA). Lundbeck didn't stop at Parkinson's. At AD/PD 2026, the company will also present research on Multiple System Atrophy (MSA), a rare but aggressive condition. Why MSA matters? * Rapid disease progression * No approved treatments * High unmet need Key areas of Focus. * Disease progression modeling (using Bayesian methods) * Biomarker development for earlier diagnosis * Patient-centric trial design These insights are shaping Lundbeck's development program for amlenetug. Amlenetug: another high-stakes bet. Amlenetug is a different kind of therapy. * A monoclonal antibody * Targets alpha-synuclein, a key protein in neurodegeneration * Aims to: * Prevent spread of toxic protein aggregates * Slow disease progression It's being developed in partnership with Genmab A/S. The bigger picture. Lundbeck is doubling down on movement disorders and neurodegeneration. This update shows: * Depth in early-stage innovation * Focus on mechanism-driven therapies * Commitment to diseases with limited treatment options Final take. This isn't a breakthrough yet - but it's a solid step. * Lu AF28996 shows early promise in a difficult indication * MSA research highlights long-term strategic thinking * The pipeline reflects a high-risk, high-reward approach If these programs succeed, Lundbeck could: * Redefine treatment in advanced Parkinson's * Enter an underserved MSA market For now, the signal is clear: early - but worth watching. Optimize your trial insights with Clival Database. Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you. Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets. With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost. To add value, Clival further break down its analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible. Elevate your trial success rate with the cutting-edge insights from Clival database.

Finans Danmark
Mar 10th, 2026
Lundbeck appoints AI director from within its own ranks.

Lundbeck appoints AI director from within its own ranks. Lundbeck has appointed Markus Kede to the new position as AI director in the pharmaceutical company. March 10, 2026 at 09:44 MarketWire AI - or artificial intelligence - is indeed a cornerstone in the company's Focused Innovator strategy. Through the technology, Lundbeck will change how the company operates, innovates, and scales. This is reported by the company in a statement. Markus Kede will be leading the development and execution of Lundbeck's AI strategy. He will start on July 1... Written for businesses. By those who know them Finans Kvartal Subscription for one user Unlimited access for 3 months Annual price: 5,180 kr Finans Årlig Subscription for one user Save 680 kr Unlimited access for 12 months Annual price: 4,500 kr Finans Business Subscription for multiple users Finans Business is for companies that want a tailored solution with multiple accesses bundled in one subscription. Payment options Try Finans for 30 days - and get access to all content. Order access

Cision
May 14th, 2025
Lundbeck Raises Financial Guidance Following Strong Start To The Year With Strategic Brands Growth Of +24% Cer

Lundbeck raises financial guidance following strong start to the year with strategic brands growth of +24% CER

INACTIVE